Marshall Wace North America’s AstraZeneca AZN Stock Holding History

Marshall Wace North America’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	$99.9M	Buy	831,635 +75,654	+10%	+$8.81M	0.43%	46
2021 Q2	$90.6M	Sell	755,981 -115,324	-13%	-$12.7M	0.38%	55
2021 Q1	$86.6M	Buy	871,305 +638,429	+274%	+$64.2M	0.36%	59
2020 Q4	$23.3M	Buy	+232,876	New	+$24.7M	0.1%	220
2020 Q3	–	Sell	-144,057	Closed	-$15.2M	–	1204
2020 Q2	$15.2M	Buy	144,057 +85,718	+147%	+$8.85M	0.1%	212
2020 Q1	$5.21M	Sell	58,339 -1,012,344	-95%	-$95.3M	0.04%	314
2019 Q4	$107M	Sell	1,070,683 -635,155	-37%	-$59.8M	0.52%	50
2019 Q3	$152M	Buy	1,705,838 +199,013	+13%	+$17.3M	0.86%	27
2019 Q2	$124M	Buy	1,506,825 +1,449,499	+2,529%	+$114M	0.77%	31
2019 Q1	$4.64M	Buy	+57,326	New	+$4.52M	0.03%	338
2018 Q3	–	Sell	-42,702	Closed	-$3M	–	927
2018 Q2	$3M	Buy	+42,702	New	+$3.07M	0.02%	655
2017 Q4	–	Sell	-17,988	Closed	-$1.22M	–	1368
2017 Q3	$1.22M	Sell	17,988 -143,876	-89%	-$9.09M	0.01%	908
2017 Q2	$11M	Buy	+161,864	New	+$10.6M	0.08%	297
2013 Q4	–	Sell	-6,347	Closed	-$330K	–	695
2013 Q3	$330K	Sell	6,347 -77,431	-92%	-$3.89M	0.01%	502
2013 Q2	$3.96M	Buy	+83,778	New	+$4.27M	0.31%	111

Other funds holding AZN

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

GQG Partners Ft. Lauderdale, Florida $53.8B AUM 19.23% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Marshall Wace North America's AZN Position: Q3 2021 in Review

Marshall Wace North America increased its AstraZeneca (AZN) stake by 10% in Q3 2021, buying an estimated $8.81M and bringing the position to 831,635 shares worth $99.9M. The position accounts for 0.43% of the portfolio, ranked #46.

Marshall Wace North America first reported a position in AZN in Q2 2013 and has held it in 15 quarters since. The position peaked at $152M in Q3 2019. 908 funds tracked by Wall St. Rank hold AZN as of Q3 2021.

Marshall Wace North America held 831,635 shares of AstraZeneca worth $99.9M as of Q3 2021.
Marshall Wace North America bought 75,654 AstraZeneca shares in Q3 2021, an estimated $8.81M.
AstraZeneca made up 0.43% of Marshall Wace North America's portfolio in Q3 2021, its #46 holding.
Marshall Wace North America first reported a position in AstraZeneca in Q2 2013 and has held it in 15 quarters since.
Marshall Wace North America's AstraZeneca position peaked at $152M in Q3 2019.
908 funds tracked by Wall St. Rank held AstraZeneca as of Q3 2021.

Based on Marshall Wace North America's 13F filing for Q3 2021, filed 15 Nov 2021.